BIOMAT Database Logo BIOMAT Database Logo

Population pharmacokinetics of busulfan in children--letter. 2012

Laurent Nguyen, and Angelo Paci, and Gilles Vassal

UI MeSH Term Description Entries
D008297 Male Males
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D018906 Antineoplastic Agents, Alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) Alkylating Agents, Antineoplastic,Alkylating Antineoplastic Agents,Alkylating Antineoplastic Drugs,Alkylating Antineoplastics,Alkylating Drugs, Antineoplastic,Antineoplastic Alkylating Agents,Antineoplastic Drugs, Alkylating,Antineoplastics, Alkylating,Antineoplastic Alkylating Drugs,Drugs, Antineoplastic Alkylating

Related Publications

Laurent Nguyen, and Angelo Paci, and Gilles Vassal
Population pharmacokinetics of oral busulfan in children.
September 2003, Cancer chemotherapy and pharmacology,
Laurent Nguyen, and Angelo Paci, and Gilles Vassal
Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
November 2011, Clinical cancer research : an official journal of the American Association for Cancer Research,
Laurent Nguyen, and Angelo Paci, and Gilles Vassal
Pharmacokinetics of high-dose busulfan in children.
January 1989, Cancer chemotherapy and pharmacology,
Laurent Nguyen, and Angelo Paci, and Gilles Vassal
Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.
November 2013, Cancer chemotherapy and pharmacology,
Laurent Nguyen, and Angelo Paci, and Gilles Vassal
Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation.
February 2008, Therapeutic drug monitoring,
Laurent Nguyen, and Angelo Paci, and Gilles Vassal
Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children.
June 2019, Pediatrics international : official journal of the Japan Pediatric Society,
Laurent Nguyen, and Angelo Paci, and Gilles Vassal
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
February 2010, Bone marrow transplantation,
Laurent Nguyen, and Angelo Paci, and Gilles Vassal
Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.
May 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Laurent Nguyen, and Angelo Paci, and Gilles Vassal
Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing.
July 2014, European journal of clinical pharmacology,
Laurent Nguyen, and Angelo Paci, and Gilles Vassal
Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation.
April 2002, British journal of clinical pharmacology,
Copied contents to your clipboard!